A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48).
Humans
Arthritis, Rheumatoid
/ drug therapy
Male
Methotrexate
/ therapeutic use
Female
Double-Blind Method
Middle Aged
Biosimilar Pharmaceuticals
/ pharmacokinetics
Antirheumatic Agents
/ pharmacokinetics
Adult
Antibodies, Monoclonal, Humanized
/ pharmacokinetics
Treatment Outcome
Aged
Severity of Illness Index
Biosimilar pharmaceuticals
Rheumatoid arthritis
Tocilizumab
Treatment switching
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
07 Sep 2024
07 Sep 2024
Historique:
received:
20
02
2024
accepted:
08
07
2024
medline:
8
9
2024
pubmed:
8
9
2024
entrez:
7
9
2024
Statut:
epublish
Résumé
Equivalent efficacy and comparable pharmacokinetic, immunogenicity, and safety profiles of the biosimilar BAT1806/BIIB800 and reference tocilizumab (TCZ) in participants with moderate-to-severe rheumatoid arthritis (RA) have been reported up to week 24 (treatment period [TP] 1) of the phase 3 study. Here we present results for TP2 (study weeks 24-48). In this phase 3, multicenter, multiregional, double-blind, active-controlled, equivalence study, participants with active RA despite methotrexate were randomized (1:1:2) to intravenous administration of 8 mg/kg TCZ every 4 weeks to week 48 (TCZ group), or TCZ to week 24 followed by BAT1806/BIIB800 to week 48 (TCZ to BAT1806/BIIB800 group), or BAT1806/BIIB800 to week 48 (BAT1806/BIIB800 group). Efficacy in TP2 was evaluated using American College of Rheumatology (ACR) response criteria (ACR20/50/70) and change from baseline in Disease Activity Score on 28 joints (DAS28). Pharmacokinetics (trough levels), safety, and immunogenicity were also evaluated. Of 621 randomized participants, 577 (92.9%) completed TP1 and entered TP2 (TCZ: N = 145 [93.5%]; TCZ to BAT1806/BIIB800: N = 142 [92.2%]; BAT1806/BIIB800: N = 290 [92.9%]). Proportions of ACR20 responders were similar between treatment groups throughout TP2 (87.8%, 90.3%, and 90.4%, respectively, at week 48), as were proportions of ACR50 and ACR70 responders, and reduction in DAS28. Drug trough levels and antidrug antibody incidences were comparable between the treatment groups. Adverse events were balanced across the treatment groups and no fatal events were reported. In TP2, efficacy, safety, immunogenicity, and pharmacokinetic profiles were comparable between the TCZ, TCZ to BAT1806/BIIB800, and BAT1806/BIIB800 groups. NCT03830203 and EudraCT 2018-002202-31.
Sections du résumé
BACKGROUND
BACKGROUND
Equivalent efficacy and comparable pharmacokinetic, immunogenicity, and safety profiles of the biosimilar BAT1806/BIIB800 and reference tocilizumab (TCZ) in participants with moderate-to-severe rheumatoid arthritis (RA) have been reported up to week 24 (treatment period [TP] 1) of the phase 3 study. Here we present results for TP2 (study weeks 24-48).
METHODS
METHODS
In this phase 3, multicenter, multiregional, double-blind, active-controlled, equivalence study, participants with active RA despite methotrexate were randomized (1:1:2) to intravenous administration of 8 mg/kg TCZ every 4 weeks to week 48 (TCZ group), or TCZ to week 24 followed by BAT1806/BIIB800 to week 48 (TCZ to BAT1806/BIIB800 group), or BAT1806/BIIB800 to week 48 (BAT1806/BIIB800 group). Efficacy in TP2 was evaluated using American College of Rheumatology (ACR) response criteria (ACR20/50/70) and change from baseline in Disease Activity Score on 28 joints (DAS28). Pharmacokinetics (trough levels), safety, and immunogenicity were also evaluated.
RESULTS
RESULTS
Of 621 randomized participants, 577 (92.9%) completed TP1 and entered TP2 (TCZ: N = 145 [93.5%]; TCZ to BAT1806/BIIB800: N = 142 [92.2%]; BAT1806/BIIB800: N = 290 [92.9%]). Proportions of ACR20 responders were similar between treatment groups throughout TP2 (87.8%, 90.3%, and 90.4%, respectively, at week 48), as were proportions of ACR50 and ACR70 responders, and reduction in DAS28. Drug trough levels and antidrug antibody incidences were comparable between the treatment groups. Adverse events were balanced across the treatment groups and no fatal events were reported.
CONCLUSION
CONCLUSIONS
In TP2, efficacy, safety, immunogenicity, and pharmacokinetic profiles were comparable between the TCZ, TCZ to BAT1806/BIIB800, and BAT1806/BIIB800 groups.
TRIAL REGISTRATION
BACKGROUND
NCT03830203 and EudraCT 2018-002202-31.
Identifiants
pubmed: 39244595
doi: 10.1186/s13075-024-03375-w
pii: 10.1186/s13075-024-03375-w
doi:
Substances chimiques
Methotrexate
YL5FZ2Y5U1
Biosimilar Pharmaceuticals
0
Antirheumatic Agents
0
tocilizumab
I031V2H011
Antibodies, Monoclonal, Humanized
0
Banques de données
ClinicalTrials.gov
['NCT03830203']
Types de publication
Journal Article
Clinical Trial, Phase III
Randomized Controlled Trial
Multicenter Study
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
157Informations de copyright
© 2024. The Author(s).
Références
Center for Drug Evaluation of the National Medical Products Administration. Technical guidelines for the development and evaluation of biosimilar drugs (in Chinese). [Internet]. 2015. https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=f044cdf4b7d7286aa12ffb85fc81a74c . Accessed January 12, 2023.
European Medicines Agency. Guideline on similar biological medicinal products [Internet]. 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf . Accessed August 16, 2022.
US Food and Drug Administration. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations [Internet]. 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-therapeutic-protein-biosimilars-comparative-analytical-assessment-and-other-quality . Accessed August 16, 2022.
Zhang H, Wang H, Wei H, Chen H, Liu J, Li C, et al. A phase I clinical study comparing the tolerance, immunogenicity, and pharmacokinetics of proposed biosimilar BAT1806 and reference tocilizumab in healthy Chinese men. Front Pharmacol. 2020;11:609522.
doi: 10.3389/fphar.2020.609522
pubmed: 33569002
Leng X, Leszczynski P, Jeka S, Liu SY, Liu H, Miakisz M, et al. Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial. Lancet Rheumatol. 2024;6(1):e40–50.
doi: 10.1016/S2665-9913(23)00237-0
pubmed: 38258678
US Department of Health and Human Services, US Food and Drug Administration. E9(R1): Statistical principles for clinical trials: addendum: estimands and sensitivity analysis in clinical trials [Internet]. 2021. https://www.fda.gov/media/148473/download . Accessed December 4, 2023.
Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis. 2016;75(11):1917–23.
doi: 10.1136/annrheumdis-2015-208426
pubmed: 26733110
Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014;73(5):803–9.
doi: 10.1136/annrheumdis-2013-204761
pubmed: 24473673
Wolff-Holz E, Tiitso K, Vleminckx C, Weise M. Evolution of the EU biosimilar framework: past and future. BioDrugs. 2019;33(6):621–34.
doi: 10.1007/s40259-019-00377-y
pubmed: 31541400
pmcid: 6875146
Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959–64.
doi: 10.1182/blood-2008-05-155846
pubmed: 18784373
Kneepkens EL, van den Oever I, Plasencia CH, Pascual-Salcedo D, de Vries A, Hart M, et al. Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study. Scand J Rheumatol. 2017;46(2):87–94.
doi: 10.1080/03009742.2016.1183039
pubmed: 27440258
Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, Nomura A, et al. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1078–85.
doi: 10.1136/annrheumdis-2016-210297
pubmed: 28007755
Gehin JE, Goll GL, Brun MK, Jani M, Bolstad N, Syversen SW. Assessing immunogenicity of biologic drugs in inflammatory joint diseases: progress towards personalized medicine. BioDrugs. 2022;36(6):731–48.
doi: 10.1007/s40259-022-00559-1
pubmed: 36315391
pmcid: 9649489
World Health Organization. Rheumatoid arthritis [Internet]. 2023. https://www.who.int/news-room/fact-sheets/detail/rheumatoid-arthritis#:~:text=In%202019%2C%2018%20million%20people,benefit%20from%20rehabilitation%20(2 ). Accessed August 18, 2023.
European Medicines Agency. Actemra (tocilizumab). Prescribing information [Internet]. https://www.ema.europa.eu/en/documents/product-information/roactemra-epar-product-information_en.pdf . Accessed August 30, 2022.
US Food and Drug Administration. Actemra (tocilizumab). Prescribing information [Internet]. 2023. https://www.gene.com/download/pdf/actemra_prescribing.pdf . Accessed July 7, 2023.